Vivus (VVUS) PT, Qsymia Sales Ramp Assumptions Cut at BofA/Merrill Lynch
Tweet Send to a Friend
BofA/Merrill Lynch analyst Steve Byrne reiterated an Underperform rating and lowered his price target on Vivus (NASDAQ: VVUS) to $4.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
